7 new domestically produced Class 1 anti-ED drugs are coming, and Yangtze River sprints for the first time! Sichuan pharmaceutical company will win the first imitation, 30 new products are on the way

A few days ago, Sichuan Haisco entered the administrative examination and approval stage with the imitation of avanafil tablets submitted for production in category 3, and is expected to win the first imitation.

The fourth domestic anti-ED oral PDE-5 inhibitor strikes, Haisco will take the first imitation The fourth domestic anti-ED oral PDE-5 inhibitor strikes, Haisco will take the first imitation

A few days ago, Sichuan Haisco entered the administrative examination and approval stage with imitation 3 types of avanafil tablets, which is expected to be approved in the near future.

A few days ago, Sichuan Haisco entered the administrative examination and approval stage with imitation 3 types of avanafil tablets, which is expected to be approved in the near future.

At present, the commonly used anti-ED oral PDE-5 inhibitors mainly include sildenafil, tadalafil, vardenafil and avanafil.

Production status of new classification of avanafil tablets

(Click on the picture to enlarge)

Source: Meinenet MED2.

The original research products have not yet been approved to enter the domestic market.

The original research products have not yet been approved to enter the domestic market.

Domestic marketed anti-ED oral PDE-5 inhibitor

Source: Meinenet MED2.

According to data from Menet.

According to data from Menet.

Over 3 billion market: Baiyunshan dominates physical pharmacies, and the hospital market will be shuffled.

According to data from Menet.

Sales of terminal anti-ED drugs in Chinese public medical institutions and physical pharmacies in Chinese cities (unit: million yuan)

Source: Minet database

The "sales champion" sildenafil is far ahead.

The "sales champion" sildenafil is far ahead.

TOP3 brands of terminal anti-ED drugs in Chinese public medical institutions and physical pharmacies in Chinese cities

Source: Minet database

In the competitive landscape of terminal anti-ED drug manufacturers in Chinese urban physical pharmacies, Baiyunshan Pharmaceutical General Factory, Pfizer, and Eli Lilly rank the top three; in the brand structure, Baiyunshan Pharmaceutical General Factory’s Sildenafil has a market share of 36.
6%.
First, the market share of original research products has gradually been eroded.

In the competitive landscape of terminal anti-ED drug manufacturers in Chinese urban physical pharmacies, Baiyunshan Pharmaceutical General Factory, Pfizer, and Eli Lilly rank the top three; in the brand structure, Baiyunshan Pharmaceutical General Factory’s Sildenafil has a market share of 36.
6%.
First, the market share of original research products has gradually been eroded.

In the terminal of public medical institutions in China, import manufacturers still dominate the market, but with the gradual advancement of centralized procurement, the market will usher in a reshuffle.
Tadalafil tablets are the second batch of collectively-sourced varieties and will be implemented in the first half of 2020.
Tasly Diyi and Changchun Haiyue are selected.
Tasly Diyi's products are squeezed into the TOP3 brand for the first time in the first half of 2020; Sildenafil is the third batch of collections.
The selection of varieties will be implemented in the second half of 2020.
Qilu will be selected exclusively.
It is expected to seize part of the market share of the original research products throughout 2020.

In the terminal of public medical institutions in China, import manufacturers still dominate the market, but with the gradual advancement of centralized procurement, the market will usher in a reshuffle.
Tadalafil tablets are the second batch of collectively-sourced varieties and will be implemented in the first half of 2020.
Tasly Diyi and Changchun Haiyue are selected.
Tasly Diyi's products are squeezed into the TOP3 brand for the first time in the first half of 2020; Sildenafil is the third batch of collections.
The selection of varieties will be implemented in the second half of 2020.
Qilu will be selected exclusively.
It is expected to seize part of the market share of the original research products throughout 2020.

Centralized procurement of anti-ED drugs

Centralized procurement of anti-ED drugs

Source: Shanghai Sunshine Pharmaceutical Purchasing Network

11 models of new drugs, 30 new products in the trial, sprint Yangtze country's first production of a class of drugs

Drug section 11, 30 in the new trial, the first country sprint Yangtze yield a class of drugs 11 models of new drugs, new 30-pending, first the country sprint Yangtze yield a class of drugs

At present, many domestic pharmaceutical companies have deployed anti-ED treatment fields.
In terms of generic drugs, there are 30 new classifications (in terms of drug name + company name) under review, involving 5 products (in terms of drug name); in terms of innovative drugs, according to incomplete statistics, there are 11 The new drug is undergoing clinical research.

At present, many domestic pharmaceutical companies have deployed anti-ED treatment fields.
In terms of generic drugs, there are 30 new classifications (in terms of drug name + company name) under review, involving 5 products (in terms of drug name); in terms of innovative drugs, according to incomplete statistics, there are 11 The new drug is undergoing clinical research.

New classification under review to report production of anti-ED drugs

New classification under review to report production of anti-ED drugs

Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

The competition for tadalafil tablets is fierce, and 13 generic drugs have been approved for production and deemed to have been reviewed.
There are currently 18 companies whose varieties are under review; sildenafil ushered in two new formulations, namely injection and oral For disintegrating tablets, the declared companies are Anrovita Pharmaceuticals and Kelun Pharmaceuticals.

The competition for tadalafil tablets is fierce, and 13 generic drugs have been approved for production and deemed to have been reviewed.
There are currently 18 companies whose varieties are under review; sildenafil ushered in two new formulations, namely injection and oral For disintegrating tablets, the declared companies are Anrovita Pharmaceuticals and Kelun Pharmaceuticals.

Research on innovative anti-ED drugs

Research on innovative anti-ED drugs

Source: China Drug Clinical Trial Publicity Library of Meinenet

Among the 11 innovative anti-ED drugs, Qilu's 2 modified new drug tadalafil oral dissolving film has been applied for marketing and is currently under review and approval.

Among the 11 innovative anti-ED drugs, Qilu's 2 modified new drug tadalafil oral dissolving film has been applied for marketing and is currently under review and approval.

Among the domestically produced Class 1 new drugs, Yangtze River/Tasly’s Eukanfil Hydrochloride Tablets has made the fastest progress and is currently undergoing Phase III clinical trials.
The product is a PDE-5 inhibitor, developed by Jilin University, Tasly applied for clinical trials, and Yangzijiang carried out clinical research.
It is expected to become the first domestically produced Class 1 new drug against ED.

Among the domestically produced Class 1 new drugs, Yangtze River/Tasly’s Eukanfil Hydrochloride Tablets has made the fastest progress and is currently undergoing Phase III clinical trials.
The product is a PDE-5 inhibitor, developed by Jilin University, Tasly applied for clinical trials, and Yangzijiang carried out clinical research.
It is expected to become the first domestically produced Class 1 new drug against ED.

The TPN729MA tablet jointly developed by Tianfang Pharmaceutical and Shanghai Institute of Materia Medica, Chinese Academy of Sciences is undergoing phase II clinical trials.
Phase I clinical trial data show that the product is superior to the marketed drug sildenafil in terms of activity, selectivity, and side effects.

The TPN729MA tablet jointly developed by Tianfang Pharmaceutical and Shanghai Institute of Materia Medica, Chinese Academy of Sciences is undergoing phase II clinical trials.
Phase I clinical trial data show that the product is superior to the marketed drug sildenafil in terms of activity, selectivity, and side effects.